GeneralBullishBlockonomi · 4h ago6/10
📰
Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results
Eli Lilly's stock gained 4% after Phase 3 trial data showed its drug retatrutide reduced sleep apnea by 60% and knee pain by 73%, demonstrating superior efficacy compared to competitor Novo Nordisk's offerings. This breakthrough in metabolic and inflammatory disease treatment positions Lilly as a leading contender in the high-growth GLP-1 and obesity-related pharmaceutical market.